Rethinking the selection of in vivo thrombosis models in the hybrid era

Abstract

Microfluidic, organoid, and in silico platforms have transformed our ability to investigate thrombosis-related biology, but preclinical in vivo models remain uniquely able to capture the interactions that shape thrombotic disease. Nevertheless, these models are not interchangeable and need to be carefully selected.